Drugs / ANAWIDOW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04848714 | Jul → Aug 2021 | black widow spider envenomation | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANAWIDOW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04848714 ↗ |
| Modality | Protein / enzyme biologic | “equine immune F(ab)2” NCT04848714 ↗ |
| Route | Intravenous | “for intravenous use” NCT04848714 ↗ |